Episode
407: The mysterious case of Eli Lilly's obesity drug
- Podcast
- The Readout Loud
- Published
- Jun 25, 2026
- Duration seconds
- 2565
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/TTSAA8014095271.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/407-the-mysterious-case-of-eli-lilly-s-obesity-drug/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/407-the-mysterious-case-of-eli-lilly-s-obesity-drug.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.